

# Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

## Purified anti-mouse CD86

RRID:AB\_313145

Type: Antibody

### Proper Citation

BioLegend Cat# 105002, RRID:AB\_313145

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_313145](http://antibodyregistry.org/AB_313145)

**Proper Citation:** BioLegend Cat# 105002, RRID:AB\_313145

**Target Antigen:** CD86

**Host Organism:** rat

**Clonality:** monoclonal

**Comments:** Applications: FC, IP, IHC-F, ICC

**Antibody Name:** Purified anti-mouse CD86

**Description:** This monoclonal targets CD86

**Target Organism:** mouse

**Clone ID:** Clone GL-1

**Antibody ID:** AB\_313145

**Vendor:** BioLegend

**Catalog Number:** 105002

**Alternative Catalog Numbers:** 105001

**Record Creation Time:** 20250820T000759+0000

**Record Last Update:** 20250820T072754+0000

### Ratings and Alerts

No rating or validation information has been found for Purified anti-mouse CD86.

No alerts have been found for Purified anti-mouse CD86.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Chemla Y, et al. (2026) HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion. *Cell*, 189(1), 233.

Shi T, et al. (2025) CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases. *Cancer cell*.

Guidi R, et al. (2023) Argonaute3-SF3B3 complex controls pre-mRNA splicing to restrain type 2 immunity. *Cell reports*, 42(12), 113515.

Okamoto M, et al. (2023) A genetic method specifically delineates Th1-type Treg cells and their roles in tumor immunity. *Cell reports*, 42(7), 112813.

Shi Q, et al. (2022) Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance. *Cancer cell*, 40(10), 1207.

Ding L, et al. (2018) PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. *Cell reports*, 25(11), 2972.